A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer

被引：0
|
作者：
Stockton, Shannon
Soares, Heloisa P.
Dayyani, Farshid
Saeed, Anwaar
Kim, Edward S.
Jin, Ning
Yacoub, George Hosni
Whisenant, Jennifer
Ayers, G. Dan
Gore, Steven
Das, Satya
Berlin, Jordan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Utah, Hunstman Canc Hosp, Salt Lake City, UT USA
[3] Univ Calif Irvine, Div Hematol Oncol, Dept Med, Orange, CA USA
[4] UPMC, Dept Med, Div Hematol & Oncol, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[5] City Hope Natl Med Ctr, Irvine, CA USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[7] Wake Forest Univ, Dept Gen Internal Med, Winston Salem, NC USA
[8] NCI, Rockville, MD USA
[9] Astra Zeneca, Gaithersburg, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4044
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Berzosertib plus irinotecan in patients with TP53 mutant gastric/gastroesophageal junction adenocarcinoma: A phase II study
    Das, Satya
    Ayers, G. Dan
    Whisenant, Jennifer
    Saeed, Anwaar
    Kim, Edward
    Florou, Vaia
    Yacoub, George
    Ivy, Percy
    Kunos, Charles
    Berlin, Jordan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [2] Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial
    Cheng, Xiangdong
    Xu, Zhiyuan
    Hu, Can
    Zhang, Yanqiang
    Pengfei, Yu
    Du, Yian
    Yang, Litao
    Zhang, Ruolan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) INCT036413131.
    Das, Satya
    Whisenant, Jennifer
    Doyle, Austin
    Allegra, Carmen Joseph
    Berlin, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [4] Oxaliplatin and capecitabine (XELOX) plus toripalimab as perioperative treatment for locally advanced gastric or gastro-esophageal junction adenocarcinoma (Neo-Capture): A single-arm, phase 2 study.
    Jiang, Zhichao
    Xie, Yibin
    Wang, Bingzhi
    Zhu, Yongjian
    Ke, Yan
    Zhang, Wen
    Sun, Yongkun
    Li, Yin
    Wang, Chengfeng
    Zhao, Dongbing
    Tian, Yantao
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16002 - E16002
  • [5] Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    Shah, Shivendra
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4647 - 4656
  • [6] Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
    Shu-Qiang Yuan
    Run-Cong Nie
    Ying Jin
    Cheng-Cai Liang
    Yuan-Fang Li
    Rui Jian
    Xiao-Wei Sun
    Ying-Bo Chen
    Wen-Long Guan
    Zi-Xian Wang
    Hai-Bo Qiu
    Wei Wang
    Shi Chen
    Dong-Sheng Zhang
    Yi-Hong Ling
    Shao-Yan Xi
    Mu-Yan Cai
    Chun-Yu Huang
    Qiu-Xia Yang
    Zhi-Min Liu
    Yuan-Xiang Guan
    Yong-Ming Chen
    Ji-Bin Li
    Xiong-Wen Tang
    Jun-Sheng Peng
    Zhi-Wei Zhou
    Rui-Hua Xu
    Feng Wang
    Nature Medicine, 2024, 30 : 552 - 559
  • [7] PHASE 2 STUDY OF TELATINIB IN COMBINATION WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED CANCER OF THE STOMACH OR GASTRO-ESOPHAGEAL JUNCTION (GEJ)
    Alsina, M.
    Ajani, J. A.
    Ko, A. H.
    Garcia De Paredes, M. L.
    Rivera, F.
    Schwartzberg, L.
    Phan, A. T.
    Whiteside, M.
    Kunkel, L. A.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 229 - 229
  • [8] A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).
    Abali, Huseyin
    Yalcin, Suayib
    Onal, Huseyin Cem
    Dane, Faysal
    Oksuzoglu, Berna
    Ozdemir, Nuriye
    Mertsoylu, Huseyin
    Artac, Mehmet
    Camci, Celalettin
    Karabulut, Bulent
    Basal, Fatma Bugdayci
    Budakoglu, Burcin
    Sendur, Mehmet Ali Nahit
    Goktas, Burce
    Ozdener, Fatih
    Calisgan, Arzu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.
    Katsuya, Hiroo
    Makiyama, Akitaka
    Kashiwada, Tomomi
    Shinohara, Yudai
    Hu, Qingjiang
    Otsu, Satoshi
    Yoneda, Akira
    Emi, Yasunori
    Ishibashi, Nobuya
    Kojiro, Eto
    Nakamura, Masato
    Shimokawa, Mototsugu
    Oki, Eiji
    Saeki, Hiroshi
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Phase I/II study of genasense (G3139) in combination with cisplatin (Cis) and fluorouracil (FU) in patients with advanced esophageal, gastro-esophageal junction and gastric cancer (P5385).
    Kaubisch, A
    Wu, YH
    Wadler, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 884S - 884S
12345